Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
As of today, Johnson & Johnson(JNJ) shares are valued at $239.92. The company's market cap stands at 586.42B, with a P/E ratio of 21.75 and a dividend yield of 2.1%.
On 2026-02-07, Johnson & Johnson(JNJ) stock traded between a low of $236.36 and a high of $241.33. Shares are currently priced at $239.92, which is +1.5% above the low and -0.6% below the high.
Johnson & Johnson(JNJ) shares are trading with a volume of 8.27M, against a daily average of 8.94M.
During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $241.33 at its peak.
During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $241.33 at its peak.
JNJ News
Johnson & Johnson announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic...
...
Johnson & Johnson (NYSE:JNJ) released new real world evidence on ERLEADA for metastatic castration sensitive prostate cancer. The study reports a significant s...
Analyst ratings
57%
of 28 ratingsMore JNJ News
If you are asking whether Johnson & Johnson’s current share price still offers value, you are not alone. That is exactly what this article is going to unpack fo...
Key Points Johnson & Johnson's growth rate improved this past year, and that trend is likely to continue. The company sees a lot of growth ahead, particularly...
Johnson & Johnson (NYSE:JNJ) reported new real-world data indicating a significant survival benefit for ERLEADA in metastatic castration-sensitive prostate canc...
RBC Capital raised the firm’s price target on Johnson & Johnson to $255 from $240 and keeps an Outperform rating on the shares. The company is unlikely to undo...
Johnson & Johnson recently reported fourth-quarter 2025 sales of US$24,564 million and full-year 2025 sales of US$94,193 million, alongside FDA approval of DARZ...
Johnson & Johnson (JNJ) is back in focus after a run of upbeat news, including strong fourth quarter and full year 2025 results, fresh 2026 sales guidance, and...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.